Primary Peritoneal Carcinoma Enrolling by Invitation Phase 2 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Enrolling by Invitation2
clinicaltrials.gov IdentifierTitlePurposeDrugs